Oil prices steady near 1-mth high on US-Iran sanctions; OPEC+ meeting awaited
Investing.com -- Bain Capital and Cinven in a joint statement on Monday said they will sell a majority stake in German drugmaker Stada Arzneimittel AG to CapVest Partners LLP, with the deal expected to close in the first half of 2026 .
Bain Capital and Cinven acquired Stada in 2017 and took it private. Under their ownership, the company expanded from a traditional generics business into a diversified healthcare platform with operations in consumer healthcare, generics and specialty pharmaceuticals.
Stada reported sales of €4.06 billion in 2024 and adjusted EBITDA of €886 million, employing about 11,600 people worldwide.
During the eight years of ownership, the firms supported more than 25 acquisitions, including Johnson & Johnson’s Nizoral brand, Czech supplement maker Walmark, and consumer health portfolios from GlaxoSmithKline and Sanofi. The acquisitions expanded Stada’s presence in Europe and other markets .
Stada’s chief executive officer Peter Goldschmidt said the company grew internationally and increased innovation under Bain and Cinven.
Dr. Michael Siefke, a partner at Bain Capital, said the firm worked to strengthen consumer healthcare, generics and specialty medicines during its investment.
Supraj Rajagopalan, co-managing partner at Cinven, said the company invested in digitalization, operational improvements and governance structures.
CapVest specializes in healthcare investments and will become the new majority owner. Bain Capital and Cinven will retain minority stakes in Stada after the transaction closes.
Jefferies and Rothschild & Co are serving as lead merger-and-acquisition advisers. The terms of the transaction were not disclosed.